Aurinia Pharmaceuticals Inc. (AUPH) — closed signal from September 8, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 7, 2025.
Predicted vs. what happened
What happened
Reached its target in 57 days.
The thesis — published September 8, 2025
AUPH's business and investor mood are improving. The price has calmed, so buying small dips can make sense. Analysts raised next-quarter profit estimates by 28%, and Q2 sales were $70M, both pointing to momentum for LUPKYNIS. As interest in biotech slowly returns, near-term upside seems possible. Still, this sector can swing, so keep positions modest and wait for confirmation.
Primary drivers
- Analysts raised profit forecasts; recent sales came in better than expected
- Price behavior improving, with space for the stock to strengthen further
- LUPKYNIS sales look steady, supporting longer-lasting business strength
- Fresh news: estimates up 28% and Q2 sales of $70M showed solid progress
How it played out
AUPH: target reached in 57 days
Lyra published AUPH at $12.36 on September 8, 2025, with 25% expected growth. The thesis pointed to improving business and investor mood, calmer price action, raised next-quarter profit estimates of 28%, Q2 sales of $70M, and steady LUPKYNIS sales. It also noted that biotech could swing.
Inside the window, the stock reached the $15.45 target in 57 days. It peaked at $16.48 on November 26, 2025, with a 33.3% gain. By December 7, 2025, it ended at $15.62. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.